uniQure Submits FDA BLA and UK MAA for Huntington's Gene Therapy AMT-130
- uniQure submitted a Biologics License Application (BLA) to the FDA for ifezuntirgene inilparvovec (AMT-130), an AAV gene therapy for Huntington's disease, and requested Priority Review.
- The company also filed a parallel Marketing Authorisation Application (MAA) with the UK's MHRA.
- AMT-130 targets the underlying genetic cause of Huntington's disease and would be the first such therapy to reach approval if cleared.
- The filings are supported by a three-year Phase I/II data analysis using a propensity-score-matched external control group from the Enroll-HD natural history database, since the trial has no concurrent placebo arm — a closely watched test of gene-therapy approval without randomized controls.
- The submission follows earlier FDA pushback on the data package before the agency aligned with uniQure; AMT-130 already holds Breakthrough Therapy, RMAT, and Fast Track designations.
First-mover matters more than usual here: Wave's WVE-003 and PTC's PTC518 are both earlier-stage, so a clean AMT-130 approval buys uniQure a real multi-year head start — once a Huntington's patient gets a one-time AAV infusion, there's no switching later. The external-control strategy is the real story though. FDA reportedly pushed back before coming around, so this reads as a precedent still being negotiated in real time, not a settled template — a green light here would embolden every small-N gene therapy sponsor; a post-approval stumble (Sarepta's the cautionary comp) would make uniQure the counterexample instead. Priority Review is less validation of the science than a compressed timeline for a single-asset story that's had its own FDA whiplash — the shorter clock is the real de-risking event for the stock, not proof the data holds up long-term.
Pharmalittle: UniQure submits Huntington's gene therapy to FDA ↗